SCHEMBL7107326

SCHEMBL7107326

c1ccc(-c2cc(Nc3cc(C4CC4)[nH]n3)nc(Sc3ccc4ccccc4c3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 10/20 0.53
AURKA O14965 2/20 0.52
NTRK1 P04629 1/20 0.52
AURKB Q96GD4 3/20 0.51
SRC P12931 1/20 0.47
GSK3B P49841 1/20 0.47
NEK1 Q96PY6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7141529 0.85 IGF1R (0.55) IGF1RAURKANTRK1AURKBSRC
SCHEMBL12510673 0.85 AURKA (0.49) IGF1RAURKANTRK1AURKBSRC
SCHEMBL13054590 0.84 IGF1R (0.47) IGF1RAURKANTRK1AURKBSRC
SCHEMBL2201374 0.84 AURKB (0.44) IGF1RAURKANTRK1AURKBSRC
SCHEMBL12430804 0.83 AURKA (0.70) AURKANTRK1AURKBSRCGSK3B
SCHEMBL12430793 0.82 NEK1 (0.58) IGF1RNEK1
SCHEMBL12430791 0.82 IGF1R (0.51) IGF1RAURKANTRK1AURKBSRC
SCHEMBL12430829 0.81 AURKB (0.77) IGF1RAURKANTRK1AURKBSRC
SCHEMBL12430534 0.80 GSK3B (0.71) AURKANTRK1AURKBSRCGSK3B
SCHEMBL12430864 0.80 IGF1R (0.53) IGF1RNEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-20030105090-A1 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA IGF1R 467/4885AURKA 3/4885NTRK1 2111/4885
US-20030105090-A1 Pyrazole compounds useful as protein kinase inhibitors AURKC, GSK3B, AURKA IGF1R 922/4885AURKA 3/4885NTRK1 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.